Study to Enroll 80 Patients Unlikely to Benefit from Venetoclax/Azacitide (Aza/Ven) Therapy in the US and Europe -- SELLAS’ Predictive ...
The automotive EBIT margin came in at 5.3%. Excluding the EUR 1.3 billion depreciation resulting from the PPA of BMW Brilliance Automotive, the EBIT margin reached 6.4% for the year. And that still ...
GPGI, Inc. (NYSE:GPGI) Q4 2025 Earnings Call Transcript March 12, 2026 GPGI, Inc. misses on earnings expectations. Reported EPS is $0.23 EPS, expectations were $0.2336. Operator: Good day, and thank ...
Study to Enroll 80 Patients Unlikely to Benefit from Venetoclax/Azacitide (Aza/Ven) Therapy in the US and Europe -- SELLAS' Predictive Biomarker and AI Assisted Precision Medicine Models to be Utilize ...
Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS) Q4 2025 Earnings Call Transcript March 12, 2026 Corvus Pharmaceuticals, Inc. misses on earnings expectations. Reported EPS is $-0.15451 EPS, expectations ...
Spyre Therapeutics, Inc. earns a Strong Buy on Phase 1 wins, IBD/RA pipeline catalysts, and $757M cash runway. Click for this ...
Bringing all of this for the year ahead, we have three core goals for FY '27, to continue executing on our multiyear growth ...
Reported Promising Data for TN-201 and TN-401 Gene Therapies in Fourth Quarter of 2025; Additional Data Readouts and Pursuit of Regulatory ...
Gulf Business on MSN
Food on the move: How Careem, talabat and noon are keeping UAE orders moving
For millions of residents in the UAE, ordering food or groceries through a smartphone app remains a routine part of daily ...
Strong enrollment momentum in Phase 1 autoimmune program evaluating prulacabtagene leucel (prula-cel, formerly ADI-001); clinical update expected in 1H/2026 with an additional update in ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results